Analysis #1a
This analysis was based on the first drug in the randomisation sequence, defining the following randomisation groups: amisulpride (n = 44), aripiprazole (n = 48) and olanzapine (n = 52). All study drugs showed relatively similar patterns of change in mPANSS in the initial phase and in the long-term phase (Fig. 
Pattern of estimated change in mPANSS among the three study drugs based on allocation in analysis #1aRegarding changes in insight, no medication differences were found in the initial phase. In the long-term phase, the amisulpride group showed a statistically significant reduction. Aripiprazole, on the other hand, showed statistically significant less reduction, showing that this group did not reduce their score (p = 0.366). Lastly, the olanzapine group did also not show reduction (p = 0.889), but this difference from the reference group was marginally beyond the 0.05 threshold (p = 0.075). These results are presented in Fig. 
Prediction of changes in mPANSS and Insight based on randomisation. Predictors are medications and changes in mPANSS. Baseline relations between mPANSS and Insight not givenInitialphaseLong-termphaseInitialPhaseLong-termphaseAnalysis #1a: Based on first drug in the randomisation sequence (n = 144)Analysis #1b: Based on the participants that chose the first drug in the randomisation sequence (n = 120)α: intercept level; I: Initial phaseL: Long-term phaseMean change: estimated absolute changes for the aripiprazole and olanzapine groups
Pattern of estimated change in insight item G12 among the three study drugs based on allocation in analysis #1aThe results also show decrease in mPANSS to be related to increase in insight in both intervals. The indirect relations between the medications and insight via mPANSS changes in the initial phase (b